Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group includes idiopathic PAH, heritable PAH (due to genetic factors), and ...
[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ... with the remaining 3 patients currently completing Part ...
Hosted on MSN2mon
Merck Phase 3 study of Winrevair in PAH meets primary endpointMerck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair ... for the treatment of adults with pulmonary arterial hypertension PAH WHO Group 1 to increase exercise capacity, improve ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback